Any AD treatment must show a clinically meaningful benefit that outweighs its risks and costs. 5 However, there is no consensus on what constitutes a “clinically meaningful” benefit for AD dementia. 6 Although it is generally agreed that cognition and functional performance should be assessed, 7 , 8 , 9 , 10 statistically significant differences in these scales in clinical trials may not always translate to a clinically meaningful effect as determined by the patient, their caregivers or family, and the treating clinician. 6 Complicating matters is that current trials of anti‐amyloid monoclonal antibodies have been restricted to persons with very mild to mild symptomatic AD, in whom functional outcomes likely differ from those with moderate or severe AD dementia.
